📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Cipla USA Initiates Recall of Lanreotide Injection Leading to Temporary Supply Shortage
Cipla Limited's wholly owned subsidiary, Cipla USA Inc., has announced a recall of all unexpired batches of Lanreotide Injection. This decision was made following discussions with Pharmathen International S.A. and will result in a temporary lack of supply for this product in the market. The recall follows previous disclosures made by the company in January and February 2026, indicating an ongoing regulatory or quality issue. This development is expected to impact the company's US revenue from this specific product line in the near term.
Key Highlights
Cipla USA Inc. to recall all unexpired batches of Lanreotide Injection from the market.
The recall will lead to a temporary lack of supply for the injection in the US market.
Decision follows discussions with partner Pharmathen International S.A. and previous updates in early 2026.
The move is a disclosure under Regulation 30 of SEBI Listing Regulations.
💼 Action for Investors
Investors should monitor the duration of the supply disruption and assess the potential impact on Cipla's US generic revenue. Watch for further management commentary on the specific reasons behind the recall and the timeline for market re-entry.
Cipla's InvaGen Facility Receives 2 USFDA Observations Post-Inspection
Cipla's wholly-owned subsidiary, InvaGen Pharmaceuticals, underwent a Pre-Approval Inspection (PAI) by the USFDA at its Hauppauge, New York facility from February 2 to February 9, 2026. Upon conclusion, the facility was issued 2 inspectional observations in Form 483. The company has committed to addressing these observations comprehensively within the stipulated timeframe. This inspection is critical as it is a Pre-Approval Inspection, which directly impacts the timeline for new product launches in the US market.
Key Highlights
USFDA conducted a Pre-Approval Inspection (PAI) at the InvaGen facility in Hauppauge, New York.
The inspection lasted 8 days, concluding on February 9, 2026.
The facility received 2 observations in Form 483 following the audit.
InvaGen Pharmaceuticals is a 100% wholly-owned subsidiary of Cipla Limited.
Cipla intends to work closely with the USFDA to resolve the issues within the required timeline.
💼 Action for Investors
Investors should monitor for further updates regarding the severity of the 2 observations, as successful resolution is necessary for upcoming product approvals. The low number of observations is generally manageable, but any escalation could delay US market expansion plans.
Cipla Faces GST Inspection at Maharashtra Facilities; Operations Unaffected
The Maharashtra Goods & Service Tax Department initiated inspection and search proceedings at Cipla's facilities and offices on February 5, 2026. The search, conducted under Section 67 of the MGST Act, focuses on tax payments, input tax credit claims, and refunds. While the proceedings are ongoing, the company has stated there is currently no financial impact or disruption to operations. Investors should monitor for any subsequent tax demands or penalties that might arise from this investigation.
Key Highlights
GST Department, Maharashtra initiated search proceedings on February 5, 2026, at 12:30 PM.
Investigation covers tax payments, input tax credit (ITC) claims, and refund processes.
Action taken under Section 67(1) and 67(2) of the Maharashtra GST Act, 2017.
Company reports no immediate financial impact or operational disruption due to the search.
💼 Action for Investors
Monitor for further disclosures regarding any tax demand notices or penalties resulting from this inspection. No immediate sell-off is warranted as operations remain normal.
Cipla Q3 FY26: Revenue flat at Rs 7,074 Cr; EBITDA margin dips to 17.7% on Revlimid decline
Cipla reported flat year-on-year revenue of Rs 7,074 crores for Q3 FY26, primarily impacted by a sharp decline in generic Revlimid sales. The One-India business remained a bright spot with 10% growth, while the North America segment recorded $167 million in revenue. Profitability was pressured, with EBITDA margins falling to 17.7% and PAT at Rs 676 crores, which included a Rs 276 crore exceptional item for labor code changes. Management lowered the full-year FY26 EBITDA margin guidance to approximately 21% due to Lanreotide supply disruptions and increased R&D investments.
Key Highlights
Revenue stood at Rs 7,074 crores (flat YoY) with EBITDA margin at 17.7% excluding other income.
One-India business grew 10% YoY, with the respiratory segment crossing Rs 5,000 crores in IPM.
Lanreotide supply is temporarily paused due to partner FDA issues, with resupply expected only in H1 FY27.
R&D spending increased by 37.4% YoY to Rs 494 crores (7% of revenue) to support the future pipeline.
Net cash position remains strong at Rs 10,229 crores despite dividend payments and acquisitions.
💼 Action for Investors
Investors should be cautious due to the lowered margin guidance and Lanreotide supply issues, though the strong India growth and healthy cash balance provide long-term support. Monitor the progress of the Indore facility re-inspection and the transition to new leadership under Achin Gupta.
Cipla Announces New Leadership Team and KMP Changes Effective April 1, 2026
Cipla Limited has announced a transition in its Key Managerial Personnel (KMP) and authorized officers, effective from April 1, 2026. The Board has designated Mr. Achin Gupta as the Managing Director and Global CEO, while Mr. Ashish Adukia will serve as the Global CFO. These individuals, along with the Company Secretary and Global General Counsel, are authorized to determine the materiality of events for SEBI disclosures. The announcement follows a board meeting held on January 23, 2026, ensuring a planned leadership succession for the pharmaceutical giant.
Key Highlights
Mr. Achin Gupta appointed as Managing Director and Global CEO effective April 1, 2026
Mr. Ashish Adukia designated as the Global Chief Financial Officer
Ms. Meera Vanjari (Global General Counsel) and Mr. Rajendra Chopra (CS) included in the authorized KMP list
Changes are made under Regulation 30(5) of SEBI Listing Regulations for materiality disclosures
The board meeting approving these changes concluded at 2:00 p.m. IST on January 23, 2026
💼 Action for Investors
Investors should monitor the transition for any changes in corporate strategy or capital allocation under the new leadership. No immediate action is required as the effective date is over two months away.
Cipla Q3 FY26: PAT Drops 57% YoY to ₹676 Cr; EBITDA Margins Contract to 17.7%
Cipla reported a challenging Q3 FY26 with flat revenue growth of 0.02% YoY at ₹7,074 crore. Profitability took a significant hit as EBITDA fell 36.9% to ₹1,255 crore and PAT plummeted 57% to ₹676 crore, impacted by rising material costs and exceptional items. While the India business showed resilience with 10% growth in branded prescriptions, the North America segment faces temporary headwinds due to a manufacturing pause for Lanreotide. The company maintains a very strong balance sheet with a net cash position of ₹10,229 crore.
Key Highlights
Revenue remained nearly flat at ₹7,074 crore compared to ₹7,073 crore in Q3 FY25.
EBITDA margins compressed significantly to 17.7% from 28.1% in the previous year's quarter.
One India business contributed 49% of total revenue, with Respiratory therapy outperforming the market by 400+ bps.
North America revenue stood at $167 million, with Albuterol maintaining a #1 market share of 22%.
Net cash position strengthened to ₹10,229 crore, providing significant capital for strategic M&A like the Inzpera acquisition.
💼 Action for Investors
Investors should monitor the recovery of EBITDA margins and the timeline for the re-supply of Lanreotide in the US market. While the India growth story and Pfizer partnership are positive, the sharp decline in quarterly profitability warrants a cautious outlook in the near term.
Cipla Q3 FY26: PAT Drops 57% YoY to ₹676 Cr Amid US Revenue Decline
Cipla reported flat revenue of ₹7,074 crore for Q3 FY26, as a 10% growth in the India business was offset by a 22% decline in North American sales following lower gRevlimid contributions. Profitability was significantly impacted, with EBITDA falling 36.9% to ₹1,255 crore and PAT declining 57% to ₹676 crore. The company increased its R&D spend by 37.4% to ₹494 crore to support its future pipeline, including four major respiratory launches planned for FY27. Despite the earnings pressure, Cipla maintains a robust net cash position of ₹10,229 crore.
Key Highlights
Consolidated PAT fell 57% YoY to ₹676 crore, while EBITDA margins contracted sharply to 17.7% from 28.1%.
India business grew 10% YoY to ₹3,457 crore, with the chronic therapy mix improving to 62.3%.
North America revenue declined 22% YoY to $167 million due to the anticipated drop in gRevlimid sales.
R&D investment rose 37.4% YoY to ₹494 crore, representing 7% of total sales to drive future filings.
Maintained a strong balance sheet with a net cash position of ₹10,229 crore as of December 2025.
💼 Action for Investors
Investors should brace for short-term volatility following the significant margin contraction and profit miss. The long-term outlook depends on the successful launch of the FY27 respiratory pipeline, including gAdvair, to replace lost gRevlimid revenue.
Cipla's Top-3 US Product Lanreotide Supply Paused Until H1 FY27 Following USFDA Observations
Cipla has confirmed a temporary production halt for Lanreotide Injection, a top-three product for its US subsidiary, following a USFDA inspection of its exclusive supplier, Pharmathen. The inspection at the Greece facility resulted in 9 observations, leading to a pause in manufacturing for remediation efforts. Re-supply to the US market is only expected to resume in the first half of FY 2026-27. This disruption is likely to impact Cipla's US revenue stream significantly until normal operations resume.
Key Highlights
Lanreotide Injection is a top 3 product for Cipla USA, making it a critical revenue driver.
Exclusive supplier Pharmathen received 9 USFDA Form 483 observations at its Greece plant.
Supply is expected to remain limited until H1 FY 2026-27, indicating a disruption of over 12 months.
The company is monitoring supply levels and is committed to remediation to restore stable supply.
💼 Action for Investors
Investors should expect near-term pressure on US sales and margins; monitor management commentary for specific revenue loss estimates and remediation progress.
Cipla Clarifies on 9 USFDA Observations at Partner Pharmathen's Greece Facility
Cipla has confirmed that its supply partner, Pharmathen International S.A., received nine inspectional observations (Form 483) from the USFDA. The inspection occurred at Pharmathen's Rodopi, Greece facility between November 10 and November 21, 2025. This facility manufactures Lanreotide Injection for Cipla's US subsidiary, a key product in its portfolio. The company is currently evaluating the material impact of these observations on its US operations.
Key Highlights
USFDA issued 9 inspectional observations in Form 483 to supply partner Pharmathen International S.A.
The affected facility in Rodopi, Greece, manufactures Lanreotide Injection for Cipla USA Inc.
Inspection was conducted over an 11-day period from November 10 to November 21, 2025.
Cipla's stock price fell 4% following media reports of these observations prior to the official clarification.
💼 Action for Investors
Investors should monitor the severity of the 9 observations as they could lead to supply disruptions for Lanreotide in the US market. Maintain a cautious stance until the company provides a detailed impact assessment or remediation timeline.
Cipla Signs 5-Year Exclusive Marketing Agreement with Pfizer for Four Key Brands
Cipla has entered into a strategic 5-year exclusive agreement with Pfizer India to market and distribute four prominent brands: Corex, Dolonex, Neksium, and Dalacin C. Under this partnership, Cipla will utilize its vast distribution network to scale these brands, while Pfizer continues to handle manufacturing and supply. The deal involves no upfront payment, representing a low-risk, high-potential expansion of Cipla's domestic portfolio. This collaboration is expected to strengthen Cipla's market share in the cough syrup, pain management, and antibiotic segments.
Key Highlights
Exclusive 5-year rights to market and distribute Corex Dx/LS, Dolonex, Neksium, and Dalacin C in India.
Partnership leverages Cipla's status as India's 3rd largest pharma company with extensive distribution reach.
Zero upfront consideration paid, with commercial terms based on ongoing supply and marketing arrangements.
Pfizer will continue to manufacture and source the medicines, ensuring consistent product quality.
💼 Action for Investors
This is a value-accretive deal that enhances Cipla's domestic portfolio with established brands; investors should maintain a positive outlook as this boosts revenue potential without capital expenditure.
Cipla launches Yurpeak® (Tirzepatide) in India for Obesity and Type 2 Diabetes
Cipla has launched Yurpeak® (Tirzepatide) in India for treating obesity and type 2 diabetes, under an agreement with Eli Lilly. Yurpeak® is a one-weekly injectable therapy and will be available in six strengths, ranging from 2.5 mg to 15 mg. Cipla will leverage its distribution network to make Yurpeak® available across India, including regions beyond metro cities. The price will be the same as Mounjaro®. This launch expands Cipla's presence in chronic disease management.
Key Highlights
Yurpeak® is available in 6 strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg
Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Sep’25)
Cipla will distribute Yurpeak® at the same price as Mounjaro®
💼 Action for Investors
Investors should monitor the market response to Yurpeak® and its impact on Cipla's revenue and profitability in the chronic disease segment. Keep an eye on Cipla's distribution strategy and market penetration in both metro and non-metro areas.
Cipla completes 100% acquisition of Inzpera Healthsciences
Cipla Limited has announced the completion of its acquisition of Inzpera Healthsciences Limited. The company acquired a 100% stake in Inzpera on December 4, 2025. As a result of this acquisition, Inzpera Healthsciences Limited has become a wholly-owned subsidiary of Cipla. This acquisition will likely expand Cipla's portfolio in the health and wellness segment.
Key Highlights
Cipla acquired 100% stake in Inzpera Healthsciences Limited
Acquisition completed on December 4, 2025
Inzpera is now a wholly-owned subsidiary of Cipla
💼 Action for Investors
Investors should monitor Cipla's future performance and integration of Inzpera to assess the long-term benefits of this acquisition. Keep an eye on how this acquisition impacts Cipla's market share and profitability in the health and wellness sector.